Adrenergic Combination Therapy for Glymphatic Flow Without Vascular Impairment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for promoting glymphatic flow in humans are based on incomplete understanding of pharmaceutical effects and have not considered the negative vascular effects of dexmedetomidine at recommended doses, leading to impaired flow.

Innovation Solution

Administering a combination of dexmedetomidine, an alpha-2A adrenergic agonist, and midodrine, an alpha-1 adrenergic agonist, at FDA-recommended doses to synergistically enhance glymphatic flow by counteracting the negative cardiovascular effects of dexmedetomidine.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If dexmedetomidine is administered at FDA-recommended doses to promote glymphatic flow, then sleep physiology is improved, but negative cardiovascular effects occur that impair glymphatic flow

Engineering Contradiction:

Improveglymphatic flow promotionVSAvoidnegative cardiovascular effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an alpha-1 adrenergic agonist as an intermediary substance that counteracts the harmful cardiovascular effects of dexmedetomidine. This intermediary mechanism allows the beneficial glymphatic flow promotion to occur while preventing the harmful side effects through pharmacological interaction.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the pharmacological parameters by combining dexmedetomidine with an alpha-1 adrenergic agonist, changing the net physiological effect on the cardiovascular system. This parameter change allows maintenance of glymphatic flow promotion while eliminating harmful cardiovascular impacts.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If prior pharmaceutical approaches are used to increase glymphatic clearance, then protein clearance is enhanced, but clinical efficacy in humans remains unconfirmed

Engineering Contradiction:

Improveprotein clearance rateVSAvoidclinical efficacy confirmation

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent incorporates clinical trial feedback from human subjects to validate and refine the treatment approach. By monitoring glymphatic flow and protein clearance in actual human patients, the study confirms efficacy and adjusts the formulation accordingly.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent performs preliminary rodent studies to establish mechanism-of-action and safety before transitioning to human clinical trials. This preliminary action allows identification of effective dosing regimens and potential side effects before human application.

Inventive Principle:

Principle #10Preliminary action

3Productivity

If high doses of dexmedetomidine are administered in rodent studies to promote glymphatic flow, then glymphatic influx is enhanced, but vascular effects are masked

Engineering Contradiction:

Improveglymphatic influxVSAvoidvascular effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using FDA-recommended human doses rather than excessive high doses, allowing the harmful vascular effects to manifest and be addressed through combination therapy. This partial approach ensures safety while maintaining therapeutic efficacy.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination significantly reduces resistance to glymphatic flow, enhances clearance of neurotoxic proteins, and improves sleep physiology, effectively treating neurodegenerative diseases like Alzheimer's and Parkinson's.

Implementation Method 1

dexmedetomidine, or a pharmaceutically acceptable salt thereof, and midodrine, or a pharmaceutically acceptable salt thereof

Methodology Applied

Scientific EffectAlpha-2A adrenergic agonism:

Implementation Method 2

midodrine, or a pharmaceutically acceptable salt thereof

Methodology Applied

Scientific EffectAlpha-1 adrenergic agonism:

Data Source

PatentUS20260000647A1Compositions, Formulations, And Methods Of Treating Neurodegenerative Diseases

Publication Date: 2026.01.01 APPLIED COGNITION INC

AI summary

The present disclosure relates to compositions, formulations, and associated methods for treating neurodegenerative diseases, wherein the compositions include an alpha-1 adrenergic agonist, such as midodrine, and an alpha-2A adrenergic agonist, such as dexmedetomidine. Upon administering to a human subject, the alpha-2A adrenergic agonist crosses the subject's blood-brain barrier thereby acting upon the subject's central nervous system, whereas the alpha-1 adrenergic agonist does not cross the subject's blood-brain barrier. The alpha-1 adrenergic agonist minimizes or eliminates the systemic vascular effects induced by the alpha-2A adrenergic agonist that causes the negative cerebral autoregulatory response, thereby enabling the alpha-2A adrenergic agonist to increase glymphatic flow in the subject's brain.